Proactive Investors - Run By Investors For Investors

Edesa Biotech soars after FDA authorizes new study of EB101 to treat dermatitis

EB101 is a topical treatment designed to halt the inflammatory process when it begins, rather than after it has occurred
skin
Edesa is developing EB101 as a treatment for chronic allergic contact dermatitis

Edesa Biotech Inc (NASDAQ:EDSA) is soaring after it reported the company received regulatory approval to proceed with its clinical study on a new dermatitis treatment.

The US Food and Drug Administration notified the biopharmaceutical company that it may proceed with its clinical investigation of EB101, which Edesa is developing as a treatment for chronic allergic contact dermatitis.

Based in Toronto, Edesa’s shares doubled to US$8.57 on Thursday at the midday point of New York trading.

READ: PreveCeutical Medical reports positive results from its dual gene therapy research program

Unlike other treatments such as steroid and anti-inflammatory drugs, EB101 is a topical treatment designed to halt the inflammatory process when it begins, rather than after it has occurred. Previous studies have demonstrated significant improvement of symptoms using EB101, according to Edesa.

The “safe to proceed” letter from the US FDA formally approves Edesa’s Phase 2b clinical protocol and authorizes the company to begin clinical investigation.

"There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the US," said Dr Par Nijhawan, CEO of Edesa. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01."

The company also has offices in southern California.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full EDSA profile View Profile

Edesa Biotech Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use